Royalty Pharma PLC 10-K filed Feb 11, 2026

Modified · Overview

We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. Since our founding in 1996, we have been pioneers in the royalty market, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. We have assembled a portfolio of royalties which entitles us to payments based directly on the top-line sales of many of the industry’s leading therapies, which includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Biogen’s Tysabri and Spinraza, Roche’s Evrysdi, Johnson & Johnson’s TremfyaAstellas and Pfizer’s Xtandi, Biogen’s Tysabri and SpinrazaJohnson & Johnson’s Tremfya, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s XtandiServier’s Voranigo, Novartis’ PromactaGilead’s Trodelvy, Pfizer’s Nurtec ODT, Gilead’s TrodelvyAmgen’s Imdelltra and Alnylam’s Amvuttra, among others, and 1420 development-stage product candidates. We fund innovation in the biopharmaceutical industry both directly and indirectly - directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when we acquire existing royalties from the original innovators.